Pyrimidine compounds and their use

Details Pyrimidine compounds and their use Pyrimidine compounds and their use

2007-07-24

2007-07-24

Balasubramanian, Venkataraman (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S269000, C544S317000, C544S320000, C544S321000, C544S322000

Reexamination Certificate

active

10618868

ABSTRACT:
A compound of the general formula (I):wherein R1, R2, X, Y and Z are as described in the specification.

REFERENCES:
patent: 3253989 (1966-05-01), Moser et al.
patent: 4078063 (1978-03-01), Lumma, Jr. et al.
patent: 4081542 (1978-03-01), Lumma, Jr. et al.
patent: 5447931 (1995-09-01), Baroni et al.
patent: 2202385 (1972-01-01), None
patent: 0226842 (1987-07-01), None
patent: 0330263 (1988-02-01), None
patent: 0345808 (1989-12-01), None
patent: 0370560 (1990-05-01), None
patent: 0462638 (1991-12-01), None
patent: 0572863 (1994-01-01), None
patent: 0580465 (1994-01-01), None
patent: 0655440 (1995-05-01), None
patent: 0657426 (1995-06-01), None
patent: 0657426 (1996-03-01), None
patent: 0655440 (1996-11-01), None
patent: 0863136 (1998-09-01), None
patent: 1023898 (2000-08-01), None
patent: 514549 (1982-07-01), None
patent: 07300474 (1995-11-01), None
patent: WO 87/04928 (1987-08-01), None
patent: WO 95/01976 (1995-01-01), None
patent: WO 96/11920 (1996-04-01), None
patent: WO 98/30548 (1998-07-01), None
patent: WO 98/42712 (1998-10-01), None
patent: WO 98/56768 (1998-12-01), None
patent: WO 99/11619 (1999-03-01), None
patent: WO 99/58490 (1999-11-01), None
patent: WO 99/58490 (1999-11-01), None
patent: WO 00/12482 (2000-03-01), None
patent: WO 00/12482 (2000-03-01), None
patent: WO 00/12502 (2000-03-01), None
patent: WO 00/12510 (2000-03-01), None
patent: WO 00/17163 (2000-03-01), None
patent: WO 00/17170 (2000-03-01), None
patent: WO 0012475 (2000-03-01), None
patent: WO 0012481 (2000-03-01), None
patent: WO 0012481 (2000-03-01), None
patent: WO 00/35922 (2000-06-01), None
patent: WO 00/44737 (2000-08-01), None
patent: WO 00/44753 (2000-08-01), None
patent: WO 00/50401 (2000-08-01), None
patent: WO 00/76984 (2000-12-01), None
patent: WO 00/76984 (2000-12-01), None
patent: WO 00/77001 (2000-12-01), None
patent: WO 00/77002 (2000-12-01), None
patent: WO 00/77010 (2000-12-01), None
patent: WO 01/09111 (2001-02-01), None
patent: WO 01/09122 (2001-02-01), None
patent: WO 01/09122 (2001-02-01), None
patent: WO 01/09123 (2001-02-01), None
patent: WO 01/09126 (2001-02-01), None
patent: WO 01/12602 (2001-02-01), None
patent: WO 01/12603 (2001-02-01), None
Wolft Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutices, 3ed.”, Marcel Dekker, New York. 1996, pp. 451 and 596.
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Vippagunta et al., Advanced Drug Delivery Reviews 48: 3-26, 2001.
International Search Report for SE 00/01472.
Campbell et al., Simon F., “2,4-Diamino-6,7-dimethoxyquinazolines. 3. 2-(4-Heterocyclylpiperasin-1-yl) Derivatives as α1-Adrenoceptor Antagonists and Antihypertensive Agents”,J. Med. Chem., vol. 30, pp. 1794-1798, 1987.
Dourish, Colin T., “Multiple Serotonin Receptors: Opportunities for New Treatments for Obesity?”,Obesity Research, vol. 3, Suppl. 4, pp. 449S-462S, 1995.
Dukat et al., Malgorzata, “Structure-Activity Relationships fo rthe Binding of Arylpiperazines and Arylbiguanides at 5-HT3Serotonin Receptors”,J. Med. Chem., vol. 39, pp. 4017-4026, 1996.
Jenck et al., F., “The role of 5-HT2creceptors in affective disorders”,Exp. Opin. Invest. Drugs, pp. 1587-1599, 1998.
Kennett, GA, “5-HT drugs and eating disorders”,IDrugs, vol. 1, No. 4, pp. 456-470, 1998.
Lee et al., Hong Shick, “Effect of the Serontonin Agonist, MK-212, on the Body Temperature in Schizophrenia”,Society of Biological Psychiatry, vol. 31, pp. 460-470, 1992.
Leysen, Dirk C.M., “Selective 5-HT2cagonists as potential antidepressants”,IDrugs, vol. 2(2), pp. 109-120, 1999.
Lumma et al., Jr., William C., “Piperazinylpyrazines with Central Serotoninmimetic Activity”,Journal of Medicinal Chemistry, vol. 21, No. 6, pp. 536-542, 1978.
Lumma, Jr. et al., William C., “Piperazinylquinoxalines with Central Serotoninmimetic Activity”,J. Med. Chem., vol. 24, pp. 93-101, 1981.
Meltzer, Herbert Y., “Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia”,Psychopharmacology, pp. S18-S27, 1989.
Methvin et al., Isaac, “Pyrrolo[3,2,2-ij] quinoline Derivatives, a 5-HT2cReceptor Agonist with Selectivity over the 5-HT2aReceptor: Potential Therapeutic Applications for Epilepsy and Obesity”,Biiorganic&Medicinal Chemistry Letters, vol. 10, pp. 919-921, 2000.
Pavia et al., Michael R., “6-Alkoxy-N,N-disubstrituted-2-pyridinamines as Anticonvulsant Agents”,J. Med. Chem., vol. 30., pp. 1210-1214, 1987.
Pavia et al., Michael R., “6-Alkyl-N,N-disubstrituted-2-pyridinamines as Anticonvulsant Agents”,J. Med. Chem., vol. 32, pp. 1237-1242, 1989.
Rogers et al., R.J. , “Differential Effects of Novel Ligands for 5-HT Receptor Subtypes on Nonopioid Defensive Analgesia in Male Mice”,Neuroscience&Biobehavioral Reviews, vol. 15, pp. 489-495, 1991.
Roth et al., Bryan L., “The Multiplicity of Serontonin Receptors: Uselessly Diverse Molecules or an Embarrassment of Riches?”,The Neuroscientist, pp. 252-262, 2000.
Sargent et al., P.A., “5-HT2creceptor activation decreases appetite and body weight in obese subjects”,Psychopharmacology, vol. 133, pp. 309-312, 1997.
Shutske et al., Gregory M., “Synthesis of Some Piperazinylpyrazolo[3,4-b]pyridines as Selective Serotonin Re-uptake Inhibitors”,J. Heterocyclic Chem., vol. 34, pp. 789-795, 1997.
Tecott et al., Laurence H., “Eating disorder and epilepsy in mice lacking 5-HT2cserotonin receptors”,Nature, vol. 374, pp. 542-546, 1995.
Andersson, K.-E. “Treatment of the overactive bladder: possible central nervous system drug targets.” Urology 2002, 59 (Suppl 5A), 18-24.
Andersson, K-E: “Pharmacology of penile erection.” Pharmacol. Rev. 2001, 53, 417-450.
Applegate CD, Tecott, LH. “Global increases in seizure susceptibility in mice lacking 5- HT2C receptors: A behavioural analysis.” Exp. Neurol. 1998, 154, 522-530.
Arjona, A. A.; Pooler, A. M.; Lee, R. K.; Wurtman, R. J. “Effect of a 5-HT(2C) serotonin agonist, dexnorfenfluramine, on amyloid precursor protein metabolism in guinea pigs.” Brain. Res. 2002, 951, 135-140.
Chojnacka-Wojcik E, Klodzinska A, Deren-Wesolek A. “Involvement of 5-HT2C receptors in the m-CPP-induced antinociception in mice.” Pol J Pharmacol. Sep.-Oct. 1994;46(5):423-8.
Cryan JF, Lucki I. . “Antidepressant-like behavioral effects mediated by 5-Hydroxytryptamine(2C) receptors.” J Pharmacol Exp Ther. Dec. 2000;295(3):1120-6.
de Groat, W.C. “Influence of central serotoneric mechanisms on lower urinary tract function.” Urology 2002, 59 (Suppl.. 5A), 30-36.
Dhonnchadha Ban, Bourin M, Hascoet M. “Anxiolytic-like effects of 5-HT2 ligands on three mouse models of anxiety.” Behavioural Brain Research 2003 140 (1-2): 203-214.
Grottick AJ, Corrigall WA, Higgins GA. “Activation of 5-HT(2C) receptors reduces the locomotor and rewarding effects of nicotine.” Psychopharmacology (Berl). Sep. 2001;157(3):292-8.
Grottick AJ, Fletcher PJ, Higgins GA. “Studies to investigate the role of 5-HT(2C) receptors on cocaine- and food-maintained behavior.” J Pharmacol Exp Ther. Dec. 2000;295(3):1183-91.
Guarneri, L. et al. “The effects of m-CPP on bladder voiding contractions in rats are mediated by the 5-HT2A/5-HT2C receptors.” Neurourol. Urodyn. 1996, 15, 316-317.
Heisler LK, Chu HM, Tecott LH. “Epilepsy and obesity in serotonin 5-HT2C receptor mutant mice.” Ann NY Acad Sci 1998, 861, 74-78.
Isaac M. “The 5-HT2C receptor as a potential therapeutic target for the design of antiobesity and antiepileptic drugs.” Drugs Future 2001, 26, 383-393.
Millan, MJ, Peglion, JL, Lavielle G, Perrin-Monneyron S: 5-HT2C receptors mediate penile rections in rats: acti

Affiliated with

Also associated with

Rating

Pyrimidine compounds and their use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrimidine compounds and their use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidine compounds and their use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3737623